Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.

被引：0
|
作者：
Shimozaki, Keitaro
Fukuda, Koshiro
Ooki, Akira
Nakayama, Izuma
Yoshino, Koichiro
Udagawa, Shohei
Fukuoka, Shota
Osumi, Hiroki
Ogura, Mariko
Wakatsuki, Takeru
Takahari, Daisuke
Shinozaki, Eiji
Chin, Keisho
Yamaguchi, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Chemotherapy, Koto Ku, Koto, Japan
[2] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Advanved Med Dev, Tokyo, Japan
[5] Canc Inst Hosp, Japanese Fdn Canc Res, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [21] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
    Qin, Shukui
    Bai, Yuxian
    Li, Jin
    Pan, Hongming
    Luo, Suxia
    Qu, Yanli
    Ye, Feng
    Yang, Lin
    Liu, Tianshu
    Li, Wei
    Chen, Xi
    Yang, Jianwei
    Ying, Jieer
    Lin, Xiaoyan
    Zhao, Lin
    Liang, Xinjun
    Mao, Yixiang
    Guo, Run
    Zuo, Yi
    Bordia, Sonal
    Li, Shouguo
    ADVANCES IN THERAPY, 2025, : 1892 - 1906
  • [22] Real-world efficacy and biomarker of nivolumab for advanced gastric cancer
    Kawabata, Ryohei
    Kurokawa, Yukinori
    Hagi, Takaomi
    Omori, Takeshi
    Matsuyama, Jin
    Fujitani, Kazumasa
    Hirao, Motohiro
    Akamaru, Yusuke
    Takahashi, Tsuyoshi
    Yamasaki, Makoto
    Satoh, Taroh
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023
    Shimozaki, Keitaro
    Ooki, Akira
    Yoshino, Koichiro
    Tamba, Mikako
    Udagawa, Shohei
    Osumi, Hiroki
    Fukuoka, Shota
    Nakayama, Izuma
    Wakatsuki, Takeru
    Ogura, Mariko
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [24] Efficacy and safety analysis of first-line tirelizumab combined with paclitaxel-containing chemotherapy regimen in 30 cases of real-world advanced gastric cancer in China
    Liu, Meng
    Zhao, Wenjun
    Cheng, Zhiqiang
    Zhang, Jincheng
    Xiong, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] The role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011-2023.
    Shimozaki, Keitaro
    Ooki, Akira
    Yoshino, Koichiro
    Tamba, Mikako
    Udagawa, Shohei
    Osumi, Hiroki
    Wakatsuki, Takeru
    Ogura, Mariko
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [26] Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer
    Xu, Mengli
    Meng, Xiangrui
    Lu, Yao
    Wang, Feng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 548 - 558
  • [27] Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.
    Kusumoto, Tetsuya
    Hashimoto, Kenkichi
    Yoshinaga, Keiji
    Kusumoto, Eiji
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    Oki, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Efficacy and Safety of First-Line Palliative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) in HER2-Negative Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Institutional Real-World Experience from Eastern India
    Chaudhuri, Tamojit
    Bankira, Jaishree
    Upadhyay, Amitabh Kumar
    Panda, Rahul
    Pandey, Vanita
    Mitra, Sujata
    Mukherjee, Sopia
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [29] Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
    Yuan, Yang
    Zhang, Shaohua
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Jiang, Zefei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
  • [30] A real-world study on implementation of new therapeutic options, especially bevacizumab, in a cohort of HER2-negative metastatic breast cancer patients treated with first-line chemotherapy
    Van Kampen, Roel J. W.
    Lobbezoo, Dorien J. A.
    De Boer, Maaike
    Voogd, Adri C.
    Dercksen, Wouter
    van den Berkmortel, Franchette W. P. J.
    Smilde, Tineke Jacoba
    Van de Wouw, Agnes W.
    Peters, Frank P. J.
    Van Riel, Johanna M. G.
    Peters, Natascha A. J. B.
    Borm, George F.
    Joore, Manuela A.
    Tjan-Heijnen, Vivianne C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345